Beigene, Ltd. (NASDAQ:ONC) Receives Average Rating of "Buy" from Brokerages

Shares of Beigene, Ltd. (NASDAQ:ONC - Get Free Report) have been given an average recommendation of "Buy" by the six ratings firms that are currently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $319.00.

Several equities research analysts have issued reports on the company. TD Securities reaffirmed a "buy" rating and set a $334.00 price target on shares of Beigene in a research note on Thursday, April 24th. JPMorgan Chase & Co. increased their price objective on Beigene from $311.00 to $317.00 and gave the company an "overweight" rating in a research report on Monday, April 21st. Guggenheim increased their price objective on Beigene from $348.00 to $350.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. JMP Securities set a $348.00 price objective on Beigene in a research report on Friday, February 28th. Finally, Bank of America upgraded Beigene from a "neutral" rating to a "buy" rating and increased their price objective for the company from $207.00 to $320.00 in a research report on Monday, March 3rd.

Insider Buying and Selling

In related news, insider Xiaodong Wang sold 41,760 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $223.50, for a total transaction of $9,333,360.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Xiaobin Wu sold 30,654 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $240.74, for a total value of $7,379,643.96. The disclosure for this sale can be found here. Insiders have sold a total of 1,187,808 shares of company stock worth $304,531,660 in the last ninety days. 6.62% of the stock is owned by insiders.

Beigene Price Performance

Shares of Beigene stock opened at $228.38 on Monday. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. Beigene has a 1 year low of $141.31 and a 1 year high of $287.88. The company has a market capitalization of $22.62 billion, a price-to-earnings ratio of -27.72, a PEG ratio of 7.73 and a beta of 0.35. The company's 50 day moving average is $243.42.

Beigene (NASDAQ:ONC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. As a group, research analysts anticipate that Beigene will post -5.82 earnings per share for the current year.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.